IP Library › Granted Patent US 12,310,943
Granted Patent B2
US 12,310,943 · App. 18/353,570 · Granted May 27, 2025

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Inventors: Christopher L. Rinsch (Lausanne, CH); William Blanco-Bose (La Croix, CH); Bernard Schneider (Pully, CH); Charles Thomas (Dijon, FR); Carmen Sandi (Bremblens, CH); Johan Auwerx (Buchillon, CH); Penelope Andreux (Eclepens, CH); Richardus Houtkooper (Weesp, NL); Eija Pirinen (Lausanne, CH); Laurent Mouchiroud (Morges, CH); David Genoux (Lausanne, CH)
Assignee: Amazentis SA
A61K31/366A23L33/105A61K9/0014A61K9/0053A61K9/0056A61K31/352A61K31/7048A61K36/185A23V2002/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,943
App. No.
18/353,570
Granted
May 27, 2025
Kind
B2
Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Claims (35)

1. A method of enhancing muscle performance, comprising administering to a mammal in need thereof an effective amount of a urolithin, thereby increasing muscle performance; wherein the effective amount of the urolithin is 300-500 mg/day, 450-750 mg/day, or 600-1000 mg/day.

2. A method of increasing or maintaining mitochondrial function, comprising administering to a mammal in need thereof an effective amount of a urolithin, thereby increasing or maintaining mitochondrial function; wherein the effective amount of the urolithin is 300-500 mg/day, 450-750 mg/day, or 600-1000 mg/day.

3. The method of claim 1 , wherein the effective amount of the urolithin is 300-500 mg/day.

4. The method of claim 3 , wherein the effective amount of the urolithin is 500 mg/day.

5. The method of claim 1 , wherein the effective amount of the urolithin is 450-750 mg/day.

6. The method of claim 1 , wherein the effective amount of the urolithin is 600-1000 mg/day.

7. The method of claim 6 , wherein the effective amount of the urolithin is 1000 mg/day.

8. The method of claim 1 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and a combination of urolithin A and urolithin B.

9. The method of claim 1 , wherein the urolithin is urolithin A.

10. The method of claim 1 , wherein the urolithin is administered orally.

11. The method of claim 1 , wherein the mammal is a human.

12. The method of claim 11 , wherein the human is elderly or frail.

13. The method of claim 1 , where the urolithin is administered in the form of a medical food.

14. The method of claim 1 , wherein the urolithin is administered in the form of a functional food.

15. The method of claim 1 , wherein the urolithin is administered in the form of a food additive.

16. The method of claim 1 , wherein the urolithin is administered in the form of a dietary supplement.

17. The method of claim 1 , wherein the urolithin is administered in the form of a food product.

18. The method of claim 2 , wherein the urolithin is urolithin A, urolithin B, urolithin C, or urolithin D; or a combination of any of them.

19. The method of claim 11 , wherein the urolithin is urolithin A.

20. The method of claim 2 , wherein the urolithin is urolithin A.

21. The method of claim 2 , wherein the effective amount of the urolithin is 300-500 mg/day.

22. The method of claim 21 , wherein the effective amount of the urolithin is 500 mg/day.

23. The method of claim 2 , wherein the effective amount of the urolithin is 450-750 mg/day.

24. The method of claim 2 , wherein the effective amount of the urolithin is 600-1000 mg/day.

25. The method of claim 24 , wherein the effective amount of the urolithin is 1000 mg/day.

26. The method of claim 2 , wherein the urolithin is administered orally.

27. The method of claim 2 , wherein the mammal is a human.

28. The method of claim 27 , wherein the human is elderly or frail.

29. The method of claim 2 , where the urolithin is administered in the form of a medical food, a functional food, a food additive, or a food product.

30. The method of claim 2 , wherein the urolithin is administered in the form of a dietary supplement.

31. The method of claim 27 , wherein the urolithin is urolithin A.

32. The method of claim 1 , wherein the urolithin is urolithin A; the effective amount of the urolithin A is 500 mg/day; the urolithin A is administered in the form of a dietary supplement; and the mammal is a human.

33. The method of claim 1 , wherein the urolithin is urolithin A; the effective amount of the urolithin A is 1000 mg/day; the urolithin A is administered in the form of a dietary supplement; and the mammal is a human.

34. The method of claim 2 , wherein the urolithin is urolithin A; the effective amount of the urolithin A is 500 mg/day; the urolithin A is administered in the form of a dietary supplement; and the mammal is a human.

35. The method of claim 2 , wherein the urolithin is urolithin A; the effective amount of the urolithin A is 1000 mg/day; the urolithin A is administered in the form of a dietary supplement; and the mammal is a human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2024
From: RINSCH, CHRISTOPHER L.; BLANCO-BOSE, WILLIAM
To: AMAZENTIS SA
Reel/Frame 068738/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2024
From: ANDREUX, PENELOPE; AUWERX, JOHAN; GENOUX, DAVID; HOUTKOOPER, RICHARDUS; MOUCHIROUD, LAURENT; PIRINEN, EIJA; SANDI, CARMEN; SCHNEIDER, BERNARD; THOMAS, CHARLES
To: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Reel/Frame 068738/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2024
From: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
To: AMAZENTIS SA
Reel/Frame 068738/0878 →
Continuity (5)
Continuation 17576502 · Jan 14, 2022
Continuation 14644912 · Mar 11, 2015
Division 13336841 · Dec 23, 2011
Provisional Application 61426957 · Dec 23, 2010
Related Publication 20240100016A1 · Mar 28, 2024
References Cited (101)
US 5411757A · Buist et al. · 1995 [cited by applicant]
US 6133311A · Bok et al. · 2000 [cited by applicant]
US 6440436B1 · Ghosal · 2002 [cited by applicant]
US 9872850B2 · Rinsch et al. · 2018 [cited by applicant]
US 10028932B2 · Rinsch et al. · 2018 [cited by applicant]
US 10485782B2 · Rinsch et al. · 2019 [cited by applicant]
US 10857126B2 · Rinsch et al. · 2020 [cited by applicant]
US 11166937B2 · Rinsch et al. · 2021 [cited by applicant]
US 11234960B2 · Rinsch et al. · 2022 [cited by applicant]
US 11903922B2 · Rinsch et al. · 2024 [cited by applicant]
US 12036205B2 · Rinsch et al. · 2024 [cited by applicant]
US 20030078212A1 · Li et al. · 2003 [cited by applicant]
US 20050282781A1 · Ghosal · 2005 [cited by applicant]
US 20070184136A1 · Aviram · 2007 [cited by applicant]
US 20080031862A1 · Ghosal · 2008 [cited by applicant]
US 20080039179A1 · Seelig et al. · 2008 [cited by applicant]
US 20080206275A1 · Ramazanov et al. · 2008 [cited by applicant]
US 20080213401A1 · Smith · 2008 [cited by applicant]
US 20080214656A1 · Lim et al. · 2008 [cited by applicant]
US 20090246300A1 · Swilling · 2009 [cited by applicant]
US 20090326057A1 · Seeram et al. · 2009 [cited by applicant]
US 20100004334A1 · Jouni et al. · 2010 [cited by applicant]
US 20100021533A1 · Mazed et al. · 2010 [cited by applicant]
US 20100055247A1 · Tirrito · 2010 [cited by applicant]
US 20210059982A1 · Rinsch et al. · 2021 [cited by applicant]
US 20220280475A1 · Rinsch et al. · 2022 [cited by applicant]
US 20240100016A1 · Rinsch et al. · 2024 [cited by applicant]
US 20240156777A1 · Rinsch et al. · 2024 [cited by applicant]
CN 101301319A · 2008 [cited by applicant]
EP 2033526A1 · 2009 [cited by applicant]
EP 2068864A2 · 2009 [cited by applicant]
EP 2654461A2 · 2013 [cited by applicant]
EP 3278800A2 · 2018 [cited by applicant]
JP H02304080A · 1990 [cited by applicant]
JP 2008503456A · 2008 [cited by applicant]
JP 2010280627A · 2010 [cited by applicant]
WO WO200015044A1 · 2000 [cited by applicant]
WO WO200149281A2 · 2001 [cited by applicant]
WO WO2003013438A2 · 2003 [cited by applicant]
WO WO2005097106A1 · 2005 [cited by applicant]
WO WO2006127832A2 · 2006 [cited by applicant]
WO WO2007127263A2 · 2007 [cited by applicant]
WO WO2008016554A1 · 2008 [cited by applicant]
WO WO2009031023A2 · 2009 [cited by applicant]
WO WO2009153652A2 · 2009 [cited by applicant]
WO WO2011011721A2 · 2011 [cited by applicant]
WO WO2012088519A2 · 2012 [cited by applicant]
WO WO2012156600A1 · 2012 [cited by applicant]
“What Is Atherosclerosis?” NHLBI, National Institutes of Health (2016). [cited by applicant]
Abstract of unexamined Japanese application No. JP2010-280627 published Dec. 16, 2010. [cited by applicant]
Basu et al., “Pomegranate juice: A heart-healthy fruit juice,” Nutr Rev, 67(1): 49-56 (2009). [cited by applicant]
Bhattacharyya et al., “Beneficial Effect of Processed Shilajit on Swimming Exercise Induced Impaired Energy Status of Mice,” Pharmacologyonline, 1: 817-825 (2009). [cited by applicant]
Bhattacharyya et al., “Shilajit Dibezno-alpha-Pyrones: Mitochondria Targeted Antioxidants,” Pharmacologyonline, 2: 690-698 (2009). [cited by applicant]
Bialonska, D et al., “Urolithins, Intestinal Microbial Metabolites of Pomegranate Ellagitannins, Exhibit Potent Antioxidant Activity in a Cell-Based Assay”, [cited by applicant]
Bishop et al., “Neural mechanisms of ageing and cognitive decline,” Nature, 464(7288):529-535 (2010). [cited by applicant]
Cerda, et al., “Identification of Urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds,” J Agric Food Chem, 53(14): 5571-5576 (2005). [cited by applicant]
Cerda, et al., “Pomegranate juice supplementation in a chronic obstructive pulmonary disease: a 5-week, randomized, double-blind, placebo-controlled trial,” Eur J Clin Nutr, 60: 245-253 (2006). [cited by applicant]
Dell'agli, et al., “Ellagitannins of fruit rind of pomegranate ( [cited by applicant]
Esmaillzadeh et al., “Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia,” J Med Food, 7(3): 305-308 (2004). [cited by applicant]
Espín et al., “Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans,” J Agric Food Chem, 55(25): 10476-10485 (2007). [cited by applicant]
Examination Report No. 2 dated Mar. 9, 2016 from corresponding Australian patent application No. 2011348068. [cited by applicant]
Extended European Search Report issued by the European Patent Office in corresponding Application No. EP18166897 issued May 28, 2018. [cited by applicant]
Gonzalez-Sarrias et al., “Dissimilar In Vitro and In Vivo Effects of Ellagic Acid and Its Microbiota-Derived Metabolites, Urolithins, on the Cytochrome P450 1A1,” Journal of Agricultural and Food Chemistry, 57: 5623-563… [cited by applicant]
Hartman, R. E. et al. “Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease”, [cited by applicant]
Hoefer et al., “Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease,” Brain, 131: 1646-1657 (2008). [cited by applicant]
International Search Report and Written Opinion from parent PCT application PCT/US2011/067229 dated Jul. 25, 2012. [cited by applicant]
Johanningsmeier et al., “Pomegranate as a functional food and nutraceutical source,” Ann Rev Food Sci Technol, 2:181-201 (2010). [cited by applicant]
Kaarniranta et al., “Age-Related Macular Degeneration (AMD): Alzheimer's Diesease in the Eye?,” Journal of Alzheimer's Disease, 24(4):615-631 (2011). [cited by applicant]
Kasimsetty, et al., “Colon cancer chemopreventive activities of pomegranate ellagitannins and Urolithins,” J Agric Food Chem, 58(4): 2180-2187 (2010). [cited by applicant]
Kharkevich, “Parmakolociva” [Pharmacology], Manual for Students of Medical Institutes, Moscow, Meditsina, 47-48 (1987). [cited by applicant]
Larossa, M. et al., “Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism”, [cited by applicant]
Larrosa, M. et al., “Ellagitannins, ellagic acid and vascular health”, [cited by applicant]
Lee, H.-J. et al., “β-Secretase (BACE1) Inhibitors from Sanguisorbae Radix”, [cited by applicant]
National Institute of Mental Health, “I'm So Stressed Out!” Fact Sheet, 2023, retrieved from https://www.nimh.nih.gov/sites/default/files/documents/health/publications/so-stressed-out-fact-sheet/Im-So-Stressed-Out.pdf, … [cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/656,096 mailed Jun. 14, 2018. [cited by applicant]
Office Action from corresponding Chinese Patent Application No. 201180067142.4 dated Jul. 3, 2014. [cited by applicant]
Office Action from corresponding Colombian Patent Application No. 12-172.849 dated Aug. 28, 2014. [cited by applicant]
Office Action from corresponding Mexican Patent Application No. MX/a/2013/007262, dated Mar. 11, 2016. [cited by applicant]
Office Action in co-pending US 2012/0164243-A1, dated Jul. 6, 2015. [cited by applicant]
Office Action in corresponding Japanese application No. JP2013-546456 dated Oct. 27, 2015. [cited by applicant]
Partial European Search Report for European Application No. 17186188.3 dated Oct. 27, 2017. [cited by applicant]
Puzzo et al., “Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines,” Biochemical Pharmacology, 88(4): 46 pages (2014). [cited by applicant]
Raza et al., “Effect of Bitter Melon ( [cited by applicant]
Raza et al., “Modulation of Xenobiotic Metabolism and Oxidative Stress in Chronic Streptozotocin-Induced Diabetic Rats Fed with Momordica charantia Fruit Extract,” J Biochem Molecular Toxicology, 14(3): 131-139 (2000). [cited by applicant]
Rock et al., “Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities,” J Agric Food … [cited by applicant]
Sanders et al., “The place of the hippocampus in fear conditioning,” European Journal of Pharmacology, 463: 217-223 (2003). [cited by applicant]
Sastre et al., “The role of mitochondrial oxidative stress in aging”, 2003, Free Radio Biol Med, 35: 1-8. [cited by applicant]
Seeram, N. P. et al., “Pomegranate Ellagitannin-Derived Metabolites Inhibit Prostate Cancer Growth and Localize to the Mouse Prostate Gland”, [cited by applicant]
Sumner et al., “Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease,” Am J Cardiol, 96(6): 810-814 (2005). [cited by applicant]
Taylor et al., “Behavioral phenotyping of mouse models of Parkinson's Disease,” Behavioural Brain Research, 211(1): 19 pages (2010). [cited by applicant]
Trombold, J. R. et al., “Ellagitannin Consumption Improves Strength Recovery 2-3 d after Eccentric Exercise”, [cited by applicant]
Verzelloni et al., “Antiglycative and Neuroprotective Activity of Colon-Derived Polyphenol Catabolites” Molecular Nutrition and Food Research, 55(1): S35-S43 (2011). [cited by applicant]
Viuda-Martos, M. et al., “Pomegranate and its Many Functional Components as Related to Human Health: A Review”, [cited by applicant]
Cintamani, “Dadima (anara) Guna” Gangavishnu Shrikrishan Das, 170 (1937). [cited by applicant]
Ibn-e-Sina, “Halelah” Institute of History of Medicine and Medical Research, 409-410 (1987). [cited by applicant]
Kabiruddin, “Rubb-e-Anaar Sheerin” Daftar-al-Maseeh, 75 (1938). [cited by applicant]
Majoosi, “Rubb-e-Rumman” Central Council for Research in Unani Medicine, 591 (2005). [cited by applicant]
Sarasamgrahah, “Anara Sarbata” Shri Baidyanath Ayurveda Bhavan Limited, 569 (2003). [cited by applicant]
Third Party Observation for Application No. EP20180166897, dated Apr. 8, 2024. [cited by applicant]
Zihong, “Practical Family Nutrition,” Wuhan University Press, p. 251 (2021). [cited by applicant]
Islam et al. “Biotransformation of 3-hydroxydibenzo-a-pyrone into 3, 8 dihydroxydibenzo-a-pyrone and aminoacyl conjugates by Aspergillus niger isolated from native “shilajit”.” Electronic Journal of Biotechnology 11.3 (… [cited by applicant]
Cited By (3)
US 12,544,358 US 12,576,064 US 12,576,065